REGistry of Long-term AnTithrombotic TherApy-2

National Medical Research Center for Cardiology, Ministry of Health of Russian Federation2,000 enrolled

Overview

To assess the rates of ischemic and hemorrhagic complications of long-term antithrombotic therapy in patients with atrial fibrillation

The register is a Russian prospective single-center observational study of patients who have indications for long-term antithrombotic therapy in connection with atrial fibrillation

Study Type

OBSERVATIONAL

Enrollment

2,000

Conditions

Atrial Fibrillation

Interventions

AnticoagulantsDRUG

oral anticoagulants, dual or triple antithrombotic theraphy

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Documented atrial fibrillation with CHA2DS2VASC \> 1 Exclusion Criteria: * Subjects who are unwilling or unable to provide informed consent. ACS within 12 months before inclusion Severe CHF (NYHA IV) Stroke within 6 months before inclusion Severe liver or muscle disease Severe kidney disease / renal failure with creatinine \> 3 mg/dl Conceivable impossibility to come in touch with the patient or his family at 1-year after the intervention

Locations (1)

National Medical Research Center for Cardiology, Ministry of Health of Russian Federation

Moscow, Russia

RECRUITING

Outcomes

Primary Outcomes

composite of major cardiovascular events

stroke, myocardial infarction, stent thrombosis \[definite or probable\], or urgent revascularization, cqrdiac death

Time frame: unclusion up to 5 years

composite of any bleeding events

major, clinically relevant nonmajor, minor (BARC, ISTH,GARFIELD AF)

Time frame: unclusion up to 5 years

Secondary Outcomes

Mutations in following genes

CYP2C9\*, VKORC1

Time frame: inclusion

Central Contacts

Ekaterina Kropacheva, PhD

CONTACT

+79166760695 katekrab@list.ru

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.